

INNOVA CAPTAB LIMITED
1281/1, Hilltop Industrial Estate,
Near EPIP, Phase-I, Jharmajri, Baddi, Dist.
Solan (H.P.)-173205 India.
Phone: +91-1795-650820



20th August, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations").

Pursuant to the Regulation 30 (read with Part A of Schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we hereby inform that the Company has successfully completed the inspection of its Cephalosporin plant, Baddi, Himachal Pradesh conducted by the United Kingdom Medicines and Healthcare products Regulatory Agency ("UK-MHRA") from 18th August to 20th August 2025 with none critical & major observations.

The aforesaid information is also being placed on the website of the Company at www.innovacaptab.com

We request you to take the same on your record.

Thanking you,

Yours faithfully,

For Innova Captab Limited

Neeharika Shukla
Company Secretary and Compliance Officer
Membership No.: A42724

Encl: A/a